This high rate of obesity may be due to the agents used in the treatment of T2DM, including insulin, sulfonylureas, and thiazolidinediones, which promote weight gain [25] Obesity increases the health risks of T2DM and complicates its management. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.